Association of SLE manifestations with SLE myopathy
| SLE manifestation | Myositis, n (%) | No myositis, n (%) | OR | P value | Adjusted OR | Adjusted p value | |
| Malar rash | 103 (57.5) | 1095 (48.6) | 1.44 (1.06–1.95) | 0.0212 | 1.67 (1.22–2.29) | 0.0014 | |
| Photosensitivity | 100 (55.9) | 1172 (52) | 1.17 (0.86–1.59) | 0.3217 | 1.43 (1.04–1.96) | 0.0273 | |
| Arthritis | 147 (82.1) | 1594 (70.8) | 1.9 (1.28–2.81) | 0.0014 | 1.81 (1.21–2.69) | 0.0035 | |
| Serositis | Pleurisy | 102 (57) | 951 (42.2) | 1.82 (1.34–2.47) | 0.0001 | 1.77 (1.3–2.42) | 0.0003 |
| Pericarditis | 56 (31.3) | 479 (21.3) | 1.68 (1.21–2.35) | 0.0021 | 1.49 (1.06–2.08) | 0.0214 | |
| Renal disorder | 11 (6.1) | 182 (8.1) | 0.74 (0.4–1.39) | 0.3556 | 0.62 (0.33–1.18) | 0.1474 | |
| Neurological | Seizures | 21 (11.7) | 210 (9.3) | 1.3 (0.8–2.09) | 0.2872 | 1.3 (0.8–2.1) | 0.2898 |
| Acute confusional state | 12 (6.7) | 69 (3.1) | 2.28 (1.21–4.29) | 0.0107 | 2.07 (1.09–3.94) | 0.0269 | |
| Haematological | Haemolytic anaemia | 23 (13.9) | 213 (9.7) | 1.5 (0.94–2.38) | 0.0863 | 1.39 (0.87–2.22) | 0.1699 |
| Leucopenia | 99 (55.3) | 1019 (45.2) | 1.5 (1.1–2.04) | 0.0096 | 1.31 (0.96–1.78) | 0.0925 | |
| Lymphopaenia | 94 (52.8) | 900 (40.2) | 1.66 (1.22–2.26) | 0.0011 | 1.64 (1.2–2.24) | 0.0017 | |
| Thrombocytopaenia | 39 (21.9) | 454 (20.2) | 1.11 (0.77–1.61) | 0.5783 | 1.09 (0.75–1.58) | 0.6589 | |
| Immunological | Anti-dsDNA | 127 (70.9) | 1376 (61.1) | 1.55 (1.11–2.17) | 0.0095 | 1.52 (1.09–2.13) | 0.0149 |
| Anti-Smith | 41 (23.3) | 443 (20.2) | 1.2 (0.83–1.73) | 0.3308 | 0.95 (0.65–1.38) | 0.7791 | |
| Antiphospholipid | Anticardiolipin | 90 (52.3) | 1047 (47.8) | 1.2 (0.88–1.63) | 0.2541 | 1.24 (0.91–1.7) | 0.173 |
| Anti-beta-2 glycoprotein | 33 (30.3) | 398 (29) | 1.06 (0.69–1.62) | 0.783 | 1.13 (0.73–1.73) | 0.5854 | |
| LAC | 53 (30.8) | 569 (26) | 1.27 (0.91–1.78) | 0.1645 | 1.42 (1–2) | 0.0478 |
P values <0.05 were considered statistically significant.
Anti-dsDNA, anti-double-stranded DNA; LAC, lupus anticoagulant.